4 assets in Sebaceous Adenocarcinoma

Therapeutic assets addressing Sebaceous Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE Sebaceous Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Sebaceous Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
mq719 Sebaceous Adenocarcinoma	Memorial Sloan Kettering Cancer Center	P1	CC (43)
Pembrolizumab Sebaceous Adenocarcinoma	Memorial Sloan Kettering Cancer Center	P1	CC (43)